Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
89.4m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
294.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
248.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Verrica Pharmaceuticals Inc
Glance View
Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Verrica Pharmaceuticals Inc is 91.4%, which is above its 3-year median of 62.1%.
Over the last 3 years, Verrica Pharmaceuticals Inc’s Gross Margin has decreased from 92% to 91.4%. During this period, it reached a low of -8% on Mar 31, 2023 and a high of 92% on Dec 31, 2022.
